Original Article
Effect of miR-200b on retinal endothelial cell function under high glucose environment

Qun Jiang¹, Fei Zhao¹, Xinmin Liu¹, Rongrong Li², Jianming Liu²

¹Department of Ophthalmology, The Second Xiangya Hospital of Central South University, Changsha 410011, China; ²The Third Xiangya Hospital of Central South University, Changsha 410013, China

Received July 28, 2015; Accepted August 28, 2015; Epub September 1, 2015; Published September 15, 2015

Abstract: As one of the important complications of diabetes, diabetic retinopathy (DR) presented high incidence worldwide. Hyperglycemia is an important promoting factor for DR occurrence and development. It can damage retinal endothelial cell, resulting in retinal structure and function disorder. Studies have shown that miR-200b may involve in regulating DR occurrence and development, but its specific function and mechanism have not been elucidated. This study aimed to investigate miR-200b effect and mechanism on human retinal endothelial cells (hRECs) under high glucose environment. hRECs were cultured under high glucose or normal environment. Real time PCR was applied to detect miR-200b expression. MiR-200b was transfected to hRECs and MTT was used to detect its effect on hRECs proliferation under high glucose environment. Real time PCR and Western blot were performed to determine VEGF and TGFβ1 expression in the retina endothelial cells. MiR-200b expression decreased significantly under high glucose environment, whereas hRECs proliferated obviously. Compared with normal control, VEGF and TGFβ1 mRNA and protein expression increased markedly (P < 0.05). After miR-200b transfection, miR-200b expression increased, while VEGF and TGFβ1 mRNA and protein expression decreased obviously. Compared with high glucose group, hRECs proliferation was inhibited (P < 0.05). MiR-200b can regulate RECs growth and proliferation by changing VEGF and TGFβ1 expression to delay DR.

Keywords: Diabetic retinopathy, retinal endothelial cell, VEGF, TGFβ1

Introduction

As one of the most important diabetes complications, diabetic retinopathy (DR) is the leading cause of blindness in adult [1, 2]. According to WHO survey, there were up to 360 million patients suffered from diabetes worldwide. It was expected to reach 1 billion till 2030 [3, 4]. The study found that diabetic retinopathy (DR) was closely related to retinal microvascular system damage caused by high glucose environment [5]. DR can change retinal structure, leading to its metabolism and function disorder. Retinal microvascular endothelial cells were responsible to supply nutritional requirements for retina nerve. They played a key role in the protection of the vision by maintaining blood-retinal barrier and removing toxins and inflammatory factors [6, 7].

MicroRNAs, also known as miRNAs or small RNAs, widely existed in animals and plants that was a kind of short chain noncoding RNA with the regulating function [8]. MiRNA can degrade mRNA and regulate protein translation through its complete or incomplete pairing with target genes, or by inhibiting the downstream target protein expression [9]. MiRNAs were mainly investigated in cancer, while they were lack of study in other diseases. MiR-200b was a new discovered miRNAs, and was reported to participate in diabetes occurrence and development [10]. It was found that miR-200b expression decreased significantly in diabetic patients, and can promote diabetes development. Thus, miR-200b was thought to play a role in diabetes occurrence and development [11]. Further study showed that miR-200b may be involved in DR occurrence and development [12]. But the specific function and mechanism of miR-200b in DR was still unclear. For hyperglycemia state can cause retinal endothelial cell (REC) injury directly or indirectly, it can lead to visual dys-
function and DR occurrence. At the same time, vascular endothelial growth factor (VEGF) and transforming growth factor β1 (TGFβ1) were confirmed to be involved in the regulation of DR lesions [13, 14]. This study tended to study miR-200b impact on RECs under high glucose and effect in regulating VEGF and TGFβ1, to analyze its role in DR.

Table 1. Primer sequence

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward 5′-3′</th>
<th>Reverse 5′-3′</th>
</tr>
</thead>
<tbody>
<tr>
<td>GADPH</td>
<td>AGTGCCAGCCTCGTCATAG</td>
<td>CGTTGAACTTGGCGTGGTGA</td>
</tr>
<tr>
<td>Mir-200b</td>
<td>AGCGGCTCATATAACAAATGG</td>
<td>GGCCGACATTCCTCCTCGTA</td>
</tr>
<tr>
<td>VEGF</td>
<td>AAACCTGTCACGGTCCGAGA</td>
<td>TCAGGGGCCGATTAAAGCTC</td>
</tr>
<tr>
<td>TGFβ1</td>
<td>GCCAGGATAGAGTTTGGGA</td>
<td>GGGTCATGTCCTCGCTCGT</td>
</tr>
</tbody>
</table>

Materials and methods

Reagents and instruments

Human retinal endothelial cells were bought from Angio-Proteomie (USA). Human microvascular endothelial cell medium was got from Cell Applications. Penicillin-streptomycin and EDTA were purchased from Hyclone (USA). DMSO and MT were bought from Gibco. Enzyme-EDTA was acquired from Sigma. PVDF membrane was got from Pall Life Science. RNA extraction kit, reverse transcription kit, and lipo2000 were bought from Invtrogen. Western blot related reagents were from Beyotime (Shanghai, China). ECL reagent was got from Amersham Biociences. Rabbit anti human VEGF and TGFβ1 antibodies, and HRP tagged IgG secondary antibody was got from Cell signaling (USA). DNA amplifier was bought from PE Gene Amp PCR System 2400 (USA). Other common reagents were from Sangon (Shanghai, China).

hRECs culture and grouping

hRECs at 3rd-8th generations were seeded in dish at 1×10⁶ cells/cm² with neural cell medium containing no fetal bovine serum DMEM medium (containing 100 U/ml penicillin and 100 μg/ml streptomycin), 5.5 mmol/L glucose. The cells were randomly divided into three groups, including normal control group; the cells were cultured under normal condition; High glucose group: high glucose environment was applied to induced culture cells, and the hRECs in logarithmetic stage was maintained in microvascular endothelia cells medium with 33 mmol/L glucose after 72 h; MiR-200b: RGC-5 cells transfected with miR-200b were cultured under high glucose.
MiR-200b delay DR development

MiR-200b mimics tranfection

MiR-200b mimics was synthesized by Gene-pharma in Shanghai. The sequence of miR-200b mimics was 5′-UAAU-AUCUGCCUGUAAUGAUGAC-3′. Lipo2000 reagent was used to transfect miR-200b to hRECs under high glucose environment. hRECs in logarithmic growth phase seeded in 6-well plate at 3×10⁶ cells/cm² and maintained in 5% CO₂ incubator at 37°C for 12 h. Then lipo2000 mixed with miR-200b mimics were added to the cells and incubated for 6 h. The cells were further cultured after changing the medium.

Real-time PCR

mRNAs were extracted from hRECs by Trizol. Real-time PCR was applied to detect target gene expression using the primers in Table 1. PCR reaction contained 52°C for 1 min, followed by 35 cycles including 90°C for 30 s, 58°C for 50 s and 72°C for 35 s. Gene expression levels were quantified relative to the expression of GAPDH using an optimized comparative Ct (2^ΔΔCt) value method.

MTT

The cells were seeded in 96-well plate at 3000/well with five replication. 20 μl MTT solution at 5 g/L was added to each well and the plate was incubated for 4 h. After removing the supernatant, 150 μl DMSO was added for 10 min and the absorbance value at 570 nm was read to calculate cell proliferation rate.

Western blot

Total protein was extracted from hRECs by lysate with ultrasound. After centrifuged at 10000× g for 15 min, the supernatant was moved to new Ep tube and stored at -20°C. The protein was separated by 10% SDS-PAGE electrophoresis and transferred to PVDF membrane. After blocked by 5%...
MiR-200b delay DR development

skim milk for 2 h, the membrane was incubated with VEGF antibody (1:1000) or TGFβ1 antibody (1:2000) at 4°C overnight. After washed by PBST, the membrane was further incubated with goat anti rabbit secondary antibody (1:2000) for 30 min and imaged with chemiluminescent agent. The band was calculated by Quantity one software with four replication.

Statistical analysis

All statistical analyses were performed using SPSS16.0 software (Chicago, IL). Numerical data were presented as means and standard deviation (x ± S). Differences between multiple groups were analyzed by one-way ANOVA. P < 0.05 was considered as significant difference.

Results

MiR-200b expression in hRECs

Real-time PCR was applied to detect miR-200b expression in hRECs. As shown in Figure 1, miR-200b expressed highly in normal hRECs, while it decreased obviously under high glucose environment (P < 0.05). MiR-200b mimics transfection to hRECs under high glucose environment can elevate miR-200b level significantly (P < 0.05).

MiR-200b effect on hRECs proliferation

MTT was performed to test miR-200b effect on hRECs proliferation under high glucose. It was found that high glucose environment promote hRECs proliferation significantly (P < 0.05). After transfecting miR-200b mimics, hRECs proliferation under high glucose was suppressed markedly (P < 0.05) (Figure 2). It revealed that miR-200b reduction can promote retinal endothelial cell growth significantly, and targeting miR-200b can inhibit retinal endothelial cell proliferation.

MiR-200b impact on VEGF and TGFβ1 mRNA expression in hRECs

MiR-200b impact on VEGF and TGFβ1 mRNA expression in hRECs under high glucose was detected by real-time PCR. VEGF and TGFβ1 mRNA expression in hRECs elevated significantly under high glucose (P < 0.05). MiR-200b mimics transfection can suppress VEGF and TGFβ1 mRNA expression in hRECs under high glucose obviously (P < 0.05) (Figure 3).

MiR-200b impact on VEGF and TGFβ1 protein expression in hRECs

Western blot was further applied to determine miR-200b mimics transfection effect on VEGF and TGFβ1 protein expression in hRECs and similar results with mRNA expression was observed. VEGF and TGFβ1 protein expression level elevated in hRECs under high glucose (P < 0.05), and their levels were restrained after miR-200b mimics transfection (P < 0.05) (Figures 4 and 5). It suggested that high glucose environment can inhibit miR-200b expression in hRECs, and increase VEGF and TGFβ1 mRNA and protein expression, further cause retinal endothelial cell structure and function disorder. Targeting miR-200b to promote its expression can downregulate VEGF and TGFβ1 mRNA and protein expression, thus improve DR.

Discussion

DR was a common diabetic microvascular complication that can lead to retinal microvascular progressive damage. It seriously affected the
patients’ physical and mental health, and brought heavy mental and economic burden to the society [15]. Although medical kept on progress, DR treatment effect was still not satisfied. High glucose environment in diabetic patients can lead to retinal endothelial cells suffered a series of endocrine metabolism changes. High blood glucose is an important factor for diabetes complications occurrence and development that can cause organ structure and function abnormality [16, 17]. Retinal endothelial cells structure and function changes were the main pathological mechanism in the chronic process of diabetes. High blood glucose can result in retinal endothelial cell dysfunction including promoting cell proliferation and neovascularization through regulating endothelin and VEGF [18, 19].

As voted one of the top ten important discoveries, miRNAs participated in various processes including cell proliferation, apoptosis, signal transduction, differentiation, hormone secretion, lipometabolism and maintaining the potential of embryonic stem cells. It can regulate the body’s growth and development to make the body adapt to the environment. Recently, multiple studies focused on miRNAs effect in the regulation of tumor occurrence, development, invasion, metastasis, and other biological features [9]. Few researches investigated miRNAs in DR. MiR-200b was thought to be involved in regulating diabetes occurrence and development [10], but its role in DR had not been elucidated. Through hRECs culture and high glucose environment treatment, our study confirmed that miR-200b level decreased in hRECs under high glucose state. It was further revealed that miR-200b can inhibit hRECs abnormal proliferation by transfecting miR-200b mimics.

VEGF had a variety of subtypes that can play its role by binding with the corresponding receptor (VEGFR). Most VEGFR located on endothelial cell surface. Their specific binding can change vascular permeability and promote blood vessel formation. Thus, VEGF regulated early stage DR by changing vascular permeability, whereas it participated in the late stage DR through promoting neovascularization [20, 21]. TGFβ1 was a kind of isomer of transforming growth factor that belonged to the polypeptide growth factor. It widely distributed in the numerous cells and had many kinds of biological functions. It also played an important role in DR formation by regulating cell growth, differentiation and migration process, adjusting extracellular matrix synthesis and secretion, and participating in immunity. TGFβ1 is a type of strong regulatory factor to promote cell proliferation. It also can upregulate integrin expression, promote extracellular matrix secretion, regulate the interactions between cells and matrix, and chemotaxis macrophages to facilitate neovascularization and fibroblast growth. It also can play a role of immunosuppression by inhibiting antibody formation and lymphocyte proliferation to suppress the cytotoxic effect of CTL, NK, and LAK cells [22, 23]. However, there is still lack of investigation about TGFβ1 role in DR. Thus, we intended to study miR-200b effect in retinal endothelial cells. It was confirmed that suppressing miR-200b expression under high glucose environment may promote VEGF and TGFβ1 mRNA and protein expression to facilitate endothelial cell proliferation and neovascularization, leading to retinopathy. Upregulating miR-200b expression by mimics can reduce VEGF and TGFβ1 mRNA and protein expression, and improve endothelial cell structure and function to postpone DR progress.

To sum up, miR-200b can delay DR progress by changing VEGF and TGFβ1 expression to mediate retinal endothelial cell growth and proliferation.

Acknowledgements


Disclosure of conflict of interest

None.

Address correspondence to: Dr. Jianming Liu, The Third Xiangya Hospital of Central South University, Changsha 410013, China. Tel: +86-731-88638888; Fax: +86-731-88638888; E-mail: jianming9288@sina.com

References

[2] Mysona BA, Matragoon S, Stephens M, Mohamed IN, Farooq A, Bartasis ML, Fouda AY,


